These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37965074)

  • 21. Comparison Between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate to Advanced Stage Hepatocellular Carcinoma.
    Pan Y; Mei J; Chen J; Zhang D; Wang J; Wang X; Yi M; Zhou Z; Zhang Y; Chen M; Guo R; Xu L
    Ann Surg Oncol; 2022 Mar; 29(3):2016-2029. PubMed ID: 34637058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma.
    Liu Y; Qiao Y; Zhou M; Guo J; Lin Y; Li W; An C; Li C
    Cancer Med; 2023 Mar; 12(5):5436-5449. PubMed ID: 36254376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
    Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Shibata H; Aoki T; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Kaibori M; Hiasa Y; Kudo M;
    Cancer Med; 2023 Jan; 12(1):325-334. PubMed ID: 35666040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study.
    Zhang W; Zhang K; Liu C; Gao W; Si T; Zou Q; Guo Z; Yang X; Li M; Liu D; Mu H; Li H; Yu H; Xing W
    Front Immunol; 2023; 14():1127349. PubMed ID: 37180098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutrophil-to-Lymphocyte Ratio and Early Tumor Shrinkage as Predictive Biomarkers in Unresectable Hepatocellular Carcinoma Patients Treated With Lenvatinib, PD-1 Inhibitors, in Combination With TACE.
    Qu S; Wu D; Hu Z
    Technol Cancer Res Treat; 2023; 22():15330338231206704. PubMed ID: 37849287
    [No Abstract]   [Full Text] [Related]  

  • 26. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
    He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
    Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study.
    Wei F; Huang Q; He J; Luo L; Zeng Y
    Cancer Manag Res; 2021; 13():4233-4240. PubMed ID: 34079375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of neutrophil-to-lymphocyte ratio and early des-γ-carboxyprothrombin change ratio as a useful predictor of treatment response for hepatic arterial infusion chemotherapy against advanced hepatocellular carcinoma.
    Tsunematsu S; Suda G; Yamasaki K; Kimura M; Takaaki I; Umemura M; Ito J; Sato F; Nakai M; Sho T; Morikawa K; Ogawa K; Kamiyama T; Taketomi A; Sakamoto N
    Hepatol Res; 2017 May; 47(6):533-541. PubMed ID: 27423140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization.
    Lin LW; Ke K; Yan LY; Chen R; Huang JY
    Front Oncol; 2023; 13():1178428. PubMed ID: 37207144
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutrophil/lymphocyte ratio as a prognostic indicator of hepatic arterial infusion chemotherapy with arterial cisplatin plus continuous 5-fluorouracil.
    Tajiri K; Kawai K; Minemura M; Yasumura S; Hosokawa A; Kawabe H; Tomizawa G; Sugiyama T
    Hepatol Res; 2015 Jul; 45(7):755-63. PubMed ID: 25196816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study.
    Zhang TQ; Geng ZJ; Zuo MX; Li JB; Huang JH; Huang ZL; Wu PH; Gu YK
    Signal Transduct Target Ther; 2023 Oct; 8(1):413. PubMed ID: 37884523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
    Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
    BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of HAIC alone vs. HAIC combined with lenvatinib for treatment of advanced hepatocellular carcinoma.
    Long F; Chen S; Li R; Lin Y; Han J; Guo J; Chen Y; Li C; Song P
    Med Oncol; 2023 Apr; 40(5):147. PubMed ID: 37043113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
    Wu YL; Fulgenzi CAM; D'Alessio A; Cheon J; Nishida N; Saeed A; Wietharn B; Cammarota A; Pressiani T; Personeni N; Pinter M; Scheiner B; Balcar L; Huang YH; Phen S; Naqash AR; Vivaldi C; Salani F; Masi G; Bettinger D; Vogel A; Schönlein M; von Felden J; Schulze K; Wege H; Galle PR; Kudo M; Rimassa L; Singal AG; Sharma R; Cortellini A; Gaillard VE; Chon HJ; Pinato DJ; Ang C
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conversion surgery for advanced hepatocellular carcinoma after combination treatment of lenvatinib and camrelizumab: a case report.
    Chen Z; Chen Z; Fan W; Zou Y; Zhang Y; Shi N; Jin H
    World J Surg Oncol; 2023 Jan; 21(1):29. PubMed ID: 36721173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study.
    Sun B; Zhang L; Sun T; Ren Y; Cao Y; Zhang W; Zhu L; Guo Y; Gui Y; Liu F; Chen L; Xiong F; Zheng C
    Front Oncol; 2022; 12():982948. PubMed ID: 36172158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial.
    Lai Z; He M; Bu X; Xu Y; Huang Y; Wen D; Li Q; Xu L; Zhang Y; Wei W; Chen M; Kan A; Shi M
    Eur J Cancer; 2022 Oct; 174():68-77. PubMed ID: 35981413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study.
    Xia D; Bai W; Wang E; Li J; Chen X; Wang Z; Huang M; Huang M; Sun J; Yang W; Lin Z; Wu J; Li Z; Yang S; Zhu X; Chen Z; Zhang Y; Fan W; Mai Q; Ding R; Nie C; Feng L; Li X; Huang W; Sun J; Wang Q; Lv Y; Li X; Luo B; Wang Z; Yuan J; Guo W; Li K; Li B; Li R; Yin Z; Xia J; Han G
    Liver Cancer; 2022 Jul; 11(4):368-382. PubMed ID: 35978600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib.
    Zhang L; Yan ZP; Hou ZH; Huang P; Yang MJ; Zhang S; Zhang S; Zhang SH; Zhu XL; Ni CF; Li Q
    Front Mol Biosci; 2021; 8():624366. PubMed ID: 34124139
    [No Abstract]   [Full Text] [Related]  

  • 40. The Predictive Value of Systemic Inflammatory Factors in Advanced, Metastatic Esophageal Squamous Cell Carcinoma Patients Treated with Camrelizumab.
    Liu J; Gao D; Li J; Hu G; Liu J; Liu D
    Onco Targets Ther; 2022; 15():1161-1170. PubMed ID: 36238132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.